Loop Diuretics in Chronic Kidney Disease
Information source: Second University of Naples
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Kidney Disease
Intervention: Furosemide (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Second University of Naples Official(s) and/or principal investigator(s): Giuseppe Conte, Professor, Study Chair, Affiliation: Second University of Naples
Summary
The purpose of this study is to verify the efficacy of diuretic therapy on blood pressure
control and left ventricular mass in patients affected by chronic kidney disease
Clinical Details
Official title: Effect of Loop Diuretics Treatment on Blood Pressure Control in Phase 3-4 of Chronic Kidney Disease
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Attainment of blood pressure target (<130/80 mmHg)and evaluation of left ventricular mass by echocardiography
Secondary outcome: Adverse drug reactions, ambulatory blood pressure measure control, body volumes evaluated by bioimpedance analysis, expense of time and resources in follow-up of patients
Detailed description:
In CKD, impairment of renal function causes fluid and sodium retention and consequently
expansion of extracellular volume, which corresponds to about 5% of body weight in absence of
peripheral edema. In particular, sodium retention increases exponentially as glomerular
filtration rate declines and is of primary importance in the pathogenesis of hypertension.
Therefore, reduction of salt intake in renal patients allows a better blood pressure control.
Despite the evidence collected on the beneficial effects of salt restriction in CKD,
compliance with dietary prescription is generally poor in patients followed up in the real
world of clinical practice. In the presence of poor adherence to salt restriction, diuretics
agents become the cornerstone of treatment of hypertension secondary to CKD. Disappointingly,
nephrologists are reluctant to "adequately" use loop diuretics in their hypertensive CKD
patients, probably because of the fear of side effects and of the amazing absence in medical
literature of studies of middle-long term on diuretic efficacy. Therefore, the primary aim of
this study is to evaluate efficacy and safety of loop diuretics on blood pressure control in
patients affected by CKD.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chronic renal insufficiency in stage CKD 3 and 4 (GFR 60-15 ml/min/m2) estimated by
Cockcroft-Gault formula corrected for body surface
- Systolic blood pressure >140 mmHg in treatment with at least 1 class of
antihypertensive drugs
- Patients not in treatment from at least one month with loop diuretics
Exclusion Criteria:
- Loop diuretics treatment
- Variation of serum creatinine >30% in the last 3 months
- Steroid therapy and/or cytotoxic agents
- Edema syndromes (Nephrotic syndrome, cirrhosis, heart failure NYHA class 3 or 4)
- Neoplasia
Locations and Contacts
Nephrology Department, Second University of Naples, Naples 80138, Italy
Additional Information
Related publications: De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, Fuiano G, Conte G; investigators of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. Achievement of target blood pressure levels in chronic kidney disease: a salty question? Am J Kidney Dis. 2004 May;43(5):782-95. Review. De Nicola L, Minutolo R, Chiodini P, Zoccali C, Castellino P, Donadio C, Strippoli M, Casino F, Giannattasio M, Petrarulo F, Virgilio M, Laraia E, Di Iorio BR, Savica V, Conte G; TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006 Feb;69(3):538-45. Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, Catapano F, Cristofano C, Scalfi L, Conte G; ERIKA Study-group. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007 Feb;71(3):245-51. Epub 2006 Oct 11.
Starting date: September 2005
Ending date: September 2007
Last updated: May 24, 2007
|